Fampridin ist ein therapeutischer Fortschritt – Pro

R. Selter; B. Hemmer

doi:10.1055/s-0035-1552710

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2015; 42(09): 542-543
DOI: 10.1055/s-0035-1552710

Debatte: Pro & Kontra

Fampridin ist ein therapeutischer Fortschritt – Pro

Fampridine for the Treatment of Gait Disturbances in Patients with Multiple Sclerosis – Pro

Authors

R. Selter

¹Klinikum rechts der Isar, Klinik für Neurologie, Technische Universität München, Ismaninger Str. 22, 81675 München
B. Hemmer

¹Klinikum rechts der Isar, Klinik für Neurologie, Technische Universität München, Ismaninger Str. 22, 81675 München

²Munich Cluster for Systems Neurology (SyNergy), München

Abstract

Full Text

References

Literatur
1 Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283: 570-572
2 Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22: 47-52
3 Stefoski D, Davis FA, Faut M et al. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-77
4 van Diemen HA, Polman CH, van Dongen TM et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123-130
5 Goodman AD, Cohen JA, Cross A et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007; 13: 357-368
6 Goodman AD, Brown TR, Cohen JA et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71: 1134-1141
7 Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738
8 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502
9 Hupperts R, Lycke J, Short C et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler 2015; Apr 28; Doi: [Epub ahead of print]
10 Pike J, Jones E, Rajagopalan K et al. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol 2012; 12: 94
11 Macdonnell R, Nagels G, Sölberg Sørensen P et al. Change in Quality of Life Outcomes with Prolonged-Release Fampridine Treatment: Interim Analysis of the ENABLE Study [P03.218]. San Diego: The American Academy of Neurology's 65th AAN Annual Meeting. Tuesday, March 19, 2013